Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E23.41 EPS (ttm)1.24 Insider Own0.04% Shs Outstand6.17B Perf Week-3.83%
Market Cap179.20B Forward P/E11.31 EPS next Y2.57 Insider Trans0.00% Shs Float6.17B Perf Month-7.24%
Income7.73B PEG4.31 EPS next Q0.55 Inst Own74.20% Short Float2.00% Perf Quarter-14.11%
Sales48.85B P/S3.67 EPS this Y-12.10% Inst Trans0.18% Short Ratio3.20 Perf Half Y-15.96%
Book/sh10.82 P/B2.68 EPS next Y10.56% ROA6.10% Target Price39.44 Perf Year-8.95%
Cash/sh3.35 P/C8.67 EPS next 5Y5.43% ROE14.90% 52W Range27.96 - 35.53 Perf YTD-9.16%
Dividend1.20 P/FCF- EPS past 5Y3.80% ROI8.40% 52W High-18.30% Beta0.90
Dividend %4.13% Quick Ratio1.30 Sales past 5Y-5.60% Gross Margin80.40% 52W Low3.82% ATR0.69
Employees78300 Current Ratio1.60 Sales Q/Q7.10% Oper. Margin29.00% RSI (14)27.11 Volatility2.56% 2.42%
OptionableYes Debt/Eq0.58 EPS Q/Q-50.00% Profit Margin20.70% Rel Volume1.01 Prev Close29.00
ShortableYes LT Debt/Eq0.44 EarningsFeb 02 BMO Payout68.30% Avg Volume38.55M Price29.03
Recom2.20 SMA20-4.08% SMA50-7.46% SMA200-11.26% Volume38,910,295 Change0.10%
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Feb-07-16 10:15AM  How Analysts View Pfizer and Merck After Earnings at 24/7 Wall St.
Feb-05-16 04:13PM  Call Martin Shkreli Whatever You Want, But Not A Pharma CEO at Forbes
01:19PM  A Checkup On A Big Healthcare ETF
09:43AM  Op-ed: On IEX, let the market decide at CNBC
09:31AM  US Service Sector Grew More Slowly in January
09:20AM  String of Q4 Earnings Beat Fails to Revive Pharma ETFs
07:00AM  Pfizer's Pipeline Productivity Is Improving at Morningstar
Feb-04-16 02:29PM  Its Time to Buy This Biotech Gem
10:45AM  Merrill Lynch Has 4 Very Oversold Blue Chip Dividend Stocks to Buy Now at 24/7 Wall St.
10:30AM  Pfizer Inc. Earnings Analysis: 2015 By the Numbers
08:25AM  Finding Value Inside Opportunity - Analyst Notes on Pfizer, Lowe's Companies, Starbucks and Boeing Accesswire
Feb-03-16 02:49PM  5 Stunning Numbers From Pfizer's Q4 Report That You May Have Missed at Motley Fool
02:00PM  Food incubator Brooklyn FoodWorks opens in former Pfizer plant at
01:49PM  Global Manufacturing Activity Remained Subdued in January 2016
12:58PM  Here's Chardan's 'Conviction Sell' On Axovant
11:32AM  Eli Lilly and Co.s 4Q15 Earnings: An Overview
09:12AM  Merck gives cautious 2016 outlook as sales of top medicines lag
08:28AM  Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
07:27AM  Pfizer, J&J, Merck evaluating technologies for Zika vaccine
Feb-02-16 07:07PM  Why Axovant Sciences Shares Are Crashing at Motley Fool
06:35PM  Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street
05:45PM  Stocks End Sharply Lower as Oil Falls
04:35PM  ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16
03:39PM  Health care analyst: How to play the current biotech market ahead of earnings
02:55PM  [$$] Pfizer Beats Expectations but Guidance Disappoints at The Wall Street Journal
02:41PM  Pfizer Looks Undervalued at Morningstar
02:26PM  [$$] Pfizer says US politicians will not scupper Allergan deal at Financial Times
02:20PM  Why Opko Health's Shares Fell 20% in January at Motley Fool
02:02PM  Pfizer Leads 3 Medical Stocks Moving On Earnings Beats
01:55PM  Pfizer's Move on Alzheimer's Drug Is Bad News for Axovant
01:48PM  Pfizer 2016 forecast disappoints
01:44PM  Pfizer earnings fall but tops Street 4Q forecasts
01:09PM  Axovant Falls Back to Earth at Bloomberg
01:08PM  Recession risks warn of severe drop in the stock market at MarketWatch
12:12PM  Top-Selling Prescription Drugs Have Seen Huge Price Hikes at Fortune
11:30AM  Stocks Follow Oil Lower
10:43AM  Pfizer Halts Drug Trial, Investors Flee Axovant at Forbes
10:17AM  Axovant Sinks on Pfizer Alzheimer's Drug Blowup at TheStreet
10:11AM  Pfizer Tops Earnings Estimates at Bloomberg
10:00AM  Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints
09:33AM  Pfizer earnings top Wall Street estimates but outlook disappoints at USA TODAY
09:12AM  Pfizer (PFE) Stock Retreats in Pre-Market Trading on 2016 Guidance at TheStreet
08:53AM  PFIZER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:45AM  Polcari: Will Weak Economy Force Fed To Go Negative On Rates?
08:20AM  Early movers: PFE, KORS, ADM, DOW, GOOG & more at CNBC
08:13AM  Pfizer (PFE) Tops on Q4 Earnings and Revenues
08:05AM  Investors OK With Pfizer Earnings, Not OK With Guidance at 24/7 Wall St.
07:57AM  Will Gilead Follow The Pfizer Game Plan For Sales Growth? at Forbes
07:39AM  Wall Street, Iowa & oil; auto sales; Alphabet's big day vs. Apple
07:34AM  Oil drops about 3% and US stock futures sink at CNBC
07:19AM  Pfizer beats profit expectations, but provides downbeat outlook at MarketWatch
07:07AM  Q4 2015 Pfizer Inc Earnings Release - Before Market Open
06:50AM  Pfizer Beats Earnings Estimates as Sales of Top Drugs Grow at Bloomberg
06:44AM  Feb. 2 Premarket Briefing: 10 Things You Should Know at TheStreet
Feb-01-16 08:15PM  What to Watch Tuesday: Yahoo! to Reveal Cost-Cutting Plan at TheStreet
02:29PM  What to Watch in the Day Ahead - Tuesday, Feb 2 Reuters
01:25PM  What to Expect From Pfizer Earnings at 24/7 Wall St.
01:07PM  Jim Cramer: Stop Thinking So Short Term About Biotech Stocks at TheStreet
01:04PM  Jim Cramer on Pfizer (PFE): 'One of the Most Consistent Companies' at TheStreet
10:38AM  Earnings: Pharma Tends to Top Street EstimateCan PFE, MRK Repeat?
10:13AM  Earnings: Dollar Could Dent Pharma; Energy Hit by Crude's Drop at Forbes
07:30AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan at noodls
07:10AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan at noodls
06:55AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan Business Wire
01:00AM  AAPL, GE, GM, YHOO: Jim Cramer's Views at TheStreet
12:04AM  What Does Novartis Expect from Pharmaceuticals?
Jan-31-16 08:25PM  Backed by $77M in funding, Cambridge biotech moves from incubator to office at
07:21PM  Mixed Earnings Expectations For Merck And Pfizer
02:20PM  How to Trade 6 Dow Components on Jim Cramers 'Anointed' List of Stocks at TheStreet
10:10AM  Top 3 Dow Earnings for the Coming Week at 24/7 Wall St.
Jan-30-16 10:50AM  5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet at 24/7 Wall St.
Jan-29-16 03:02PM  3 Numbers That Will Matter When Pfizer Reports Its Fourth-Quarter Results at Motley Fool
03:00PM  Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?
02:34PM  Trading Next Week's Big Earnings: Alphabet & Pfizer at CNBC
02:03PM  Business events scheduled for the coming month
01:00PM  Is this a sucker's bottom?
12:58PM  Top trades for the 2nd half: Earnings ahead
12:11PM  Here's What to Know Ahead of Pfizer's (PFE) Earnings Results at TheStreet
10:54AM  Charterhouse begins groundwork for $700 mln-plus Doc Generici sale -sources
09:05AM  4 Out-Of-Favor Large-Cap Blue-Chip Dividend Stocks to Buy Now at 24/7 Wall St.
08:07AM  Johnson ControlsTyco Merger: The Pfizer-Allergan of 2016?
Jan-28-16 09:00PM  Biotech Stocks Crashed and Nobody Knows Why at Fortune
05:37PM  Heres the Company Thats the Closest to Developing a Zika Vaccine at Fortune
12:29PM  Pfizer vs. Merck -- Which Is the Better Dividend Stock Right Now? at TheStreet
10:25AM  Novartis (NVS) Lags Q4 Earnings & Revenues, Alcon Down
08:40AM  Short Sellers Become More Selective on Major Pharma at 24/7 Wall St.
08:07AM  Eylea Could Help Regeneron Focus on the Eye Therapy Segment
07:52AM  Bristol-Myers posts 4Q loss, but beats views as sales rise
Jan-27-16 04:07PM  Lillys Valuation Multiples Have Followed the Industrys Trend
02:38PM  [$$] Novartis Profit Dives 57% at The Wall Street Journal
11:22AM  Cramer: What Do You Pay for a Monster Like Apple?
10:30AM  More Squawk From Jim Cramer: Apple (AAPL) Stock Could Rise to $100 or $130 at TheStreet
08:53AM  Novartis hires Hospira's $90 mln man to save Alcon Reuters
Jan-26-16 04:00PM  Donald Trump joins Democrats in voicing drug price concer...
02:25PM  Does Trump believe Medicare should negotiate prices? at CNBC
09:48AM  Biosimilar drugs get boost as UK cost agency backs their use Reuters
08:20AM  If You're in Your 60s, Consider Buying These Stocks at Motley Fool
08:05AM  Does Marketing Have Too Much Control In Big Pharma Clinical Trials? at Forbes
07:45AM  Forget Pfizer Inc.: Here Are 2 Better Dividend Stocks at Motley Fool
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has strategic collaboration with KineMed Inc.; collaborations with BIND Therapeutics, Inc., Merck KGaA, and Syndax Pharmaceuticals, Inc.; research collaboration with Schrdinger, Inc.; license and collaboration agreement with Servier; strategic drug discovery agreement with Heptares; and collaboration agreement with Portola Pharmaceuticals Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM